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Peroral protein/peptide delivery has been one of the most challenging, but encouraging topics in pharmaceutics.
This article was intended to explore the potential of biotin-modified liposomes (BLPs) as oral insulin delivery carriers.
By incorporating biotin-DSPE into the lipid bilayer, we prepared BLPs using reverse evaporation/sonication method.
We investigated hypoglycemic effects in normal rats after oral administration of BLPs, and the possible absorption
mechanism by a series of in vitro tests. The relative pharmacological bioavailability of BLPs was up to 11.04% that
was as much as 5.28 folds of conventional liposomes (CLPs). The results showed that the enhanced oral absorption
of insulin mainly attributed to biotin ligand-mediated endocytosis. The results provided proof of BLPs as effective
carriers for oral insulin delivery.
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With the advent of biotech epoch, more and more pro-
teins and peptides become available for clinical treat-
ment, such as growth hormone [1], calcitonin [2], and
octreotide [3]. Nevertheless, due to short half-life in the
blood circulation, it is inevitable to take the medications
subjected to multi-dosage over a long time for chronic
diseases. Insulin, a protein secreted by the β cells of the
pancreas, is one of the most important therapeutic
agents for insulin-dependent (type I) and deteriorative
insulin-independent (type II) diabetes mellitus [4], and
commonly administered subcutaneously; however, besides
pain, which may bring about unwanted complications, e.g.
allergic reactions, hyperinsulinemia, insulin lipodystrophy
around the injection site [5]. Problems encountered
with insulin injection vitalize the demands to develop
alternative delivery systems.
However, to achieve effective oral delivery of insulin,
several barriers like instability, gastrointestinal enzymatic
degradation, and poor membrane permeability, etc., should* Correspondence: qijianping@fudan.edu.cn
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in any medium, provided the original work is pbe overcome beforehand [6]. Various delivery strategies,
especially those based on nanoscaled delivery systems,
have been explored to enhance the oral delivery of insulin,
including microemulsions [7], nanospheres [8], polymeric
nanoparticles [9,10], niosomes [11], and liposomes [12-14].
However, the state of the art indicates that there seems
to have reached a bottleneck in terms of oral bioavail-
ability enhancement of insulin. It is highly recom-
mended to explore novel strategies to ameliorate the
performance of nanoscaled drug delivery systems. As
known, receptor-mediated endocytosis, a process of in-
ternalization of extracellular molecules during which a
binding occurs between the molecules and the receptors,
is an important absorption mechanism for substances like
proteins, hormones, growth factors, and fatty nutrients
[15]. In the intestinal cavity, there are a variety of recep-
tors expressing on the membrane of enterocytes such as
vitamins, transferrin, amino acids, sugars, and bile salt
receptors [16]. Targeted drug delivery to absorptive epi-
thelia by receptor-mediated endocytosis has emerged as a
prominent means to improve oral delivery of drugs [17].
Vitamins as ligands, which can specifically bind to entero-
cytic receptors, have been extensively studied for the oral
delivery of poorly permeable molecules [18-22].n Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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and partially in the colon are responsible for the essential
absorption of biotin by nonspecific receptor-mediated
endocytosis [23]. Additionally, biotin plays an import-
ant role in maintaining the homeostasis of blood glu-
cose [24]. Improved cellular permeability and higher
hypoglycemic effect after oral administration of biotin-
conjugated glucagon-like peptide-1 has been observed
[25]. Biotin-modified vehicles have been investigated
for nonparenteral delivery of active ingredients [26-29].
Our previous report has also proved that biotin-modified
liposomes (BLPs) have ability to improve the oral delivery
of insulin, and studied the uptake and transport mecha-
nisms in the gastrointestinal tract [30]. However, particu-
lar enhanced absorption mechanisms and cytotoxicity of
BLPs are not clear enough.
Herein, we performed several experiments to further
probe the oral absorption mechanism of BLPs based on
previous studies [30] as well as the cytotoxicity thereof. We
evaluated hypoglycemic effects of BLPs of various particles,
or with different amounts of biotin-DSPE using normal
rats. Meanwhile, the influence of BLPs on tight junctions




Porcine insulin (29 IU/mg) was provided by Jiangsu
Wanbang Biochemical Pharmaceutical Co, Ltd (Xuzhou,
China). Soybean phosphatidylcholine (SPC, Lipoid S75),
cholesterol (CH), and 1, 2-distearoyl-sn-glycero-3-phos-
phatidyl ethanolamine (DSPE) were supplied by Lipoid
(Ludwigshafen, Germany). Fluorescein isothiocyanate (FITC)
and biotin were purchased from Sigma (Shanghai, China).
Sephadex G-50 was obtained from Pharmacia (Shanghai,
China). Deionized water was prepared by a Milli-Q purifi-
cation system (Molsheim, France). HPLC-grade acetonitrile
was provided by Merck (Darmstadt, Germany). All other
chemicals were of analytical grade and used as received.
Preparation of BLPs
SPC, biotin-DSPE (synthesized according to previous
report [30]), and cholesterol were dissolved in absolute
ether to prepare the organic phase, into which the
aqueous phase, insulin citric acid-Na2HPO4 buffer solution
(pH 4.0, if not specified otherwise), was added dropwise
following ultra-sonication to prepare the W/O emulsion.
The organic solvent in the emulsion was then evaporated
toward a rota-evaporator under 0.05- to 0.06-MPa pres-
sure at a rotating speed of 50 rpm at 30°C until glutinous
gel formed. Afterwards, citric acid-Na2HPO4 buffer with
pH 3.8 was instilled to hydrate the lipidic gel until a
homogeneous dispersion was formed. Finally, the dis-
persion was homogenized through an ultrasound cellcracker (SCIENTZ IID, Scientz Biotechnology, Ningbo,
China) to obtain insulin-loaded BLPs. To prepare insulin-
loaded conventional liposomes (CLPs) and blank liposomes,
same procedures were followed as described above.
The particle size of liposomes was measured by dynamic
light scattering using Zetasizer Nano ZS (Malvern,
Worcestershire, UK) at 25°C. The morphology of the
liposomes was characterized by transmission electron
microscopy (TEM). Briefly, liposomes were dripped onto a
piece of copper grid and negatively stained with 1% (w/v)
phosphotungstic acid for 1 min at room temperature.
The stained nanoparticles allowed to dry at ambient
condition and then were observed with TEM (JEM-1230,
Tokyo, Japan) at an acceleration voltage of 120 kV.
Entrapment efficiency
Entrapment efficiency of insulin-loaded liposomes was
determined by molecular exclusion chromatography
using Sephadex G50 column to separate the free insulin
from liposomes [31]. Briefly, liposome samples were
added into the top of column and eluted with the same
buffer to liposomes hydration. The eluted fraction of
insulin-enveloped liposomes was analyzed by HPLC ac-
cording to the reported procedure [32]. The entrapment
efficiency (EE) was defined as the ratio of liposome-
enveloped insulin (insulinenv) to total insulin (insulintot),
namely EE (%) = Insulinenv/Insulintot × 100%.
Hypoglycemic effect in normal rats
Normal rats (SD, 220 ± 20 g), supplied by Shanghai
Laboratory Animal Resource Center, were applied to
the evaluation of the hypoglycemic effect. The rats were
fasted for 12 h ahead of administration, but allowed free
access to water during the sampling. All animal experi-
ments were conducted in accordance with the approval
of Experimental Animal Ethical Committee of Fudan
University. The intragastric (i.g.) dose of liposomes was
equivalent to 20 IU/kg of insulin, while the subcutane-
ous (s.c.) dose of insulin solution as reference was set to
1 IU/kg. Blood samples (150 μL) were collected from
the tail vein at specific intervals into heparinized tubes,
and immediately centrifuged at 5,000 g for 5 min to
gather the plasma. Blood glucose was determined in
triplicate by the glucose oxidase method using Glucose
GOD-PAD kit (Rongsheng Biotech, Shanghai, China).
Besides, we investigated the influence of particle size,
biotin-DSPE proportion and dose of liposomes after oral
administration on the hypoglycemic effect in rats. The
relative bioavailability was calculated based on the pharma-
cological activity following the equation below:
PA %ð Þ ¼ AAC0 to 12h i:g:ð Þ  Dose s:c:ð Þ
AAC0 to 12h s:c:ð Þ  Dose i:g:ð Þ  100%
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levels vs. time curve calculated by the trapezoidal method
using a reference line obtained from the base control.
Absorption mechanism studies
In order to continue to investigate the absorption mechan-
ism, the changes of the transepithelial electrical resistance
(TEER) of Caco-2 cell monolayers after incubation with
insulin-loaded liposomes and the intracellular trafficking of
BLPs were determined. The methods of cell culture, Caco-2
cell monolayer construction and the synthesis of fluorescent
probes were the same as the previous report [30].
To determine the TEER, the well-cultured Caco-2 cell
monolayers were incubated with insulin preparations, and
the TEERs of Caco-2 cell monolayers were determined
at different times by a Millicell Electrical Resistance
System equipped with STX-2 electrodes (Millipore, Bedford,
MA, USA).
To study the intracellular trafficking of BLPs, cells
were cultured on coverslips for 5 days prior to testing.
For endosome investigation, the cells were treated with
rhodamine-labeled BLPs for 2 h. Then, the cells were con-
tinued to be incubated with Rabbit polyclonal antibody
Rab5 (ab18211, Abcam, UK) and Mouse monoclonal Rab7
(ab50533, Abcam, UK) overnight at 37°C followed by the
addition of a secondary antibody FITC-goat anti-rabbit
IgG to identify the early and later endosomes. For lysosome
investigation, the medium containing LysoTracker® Red
DND-99 g was added into the cells beforehand to label the
lysosomes for 2 h. Subsequently, the cells washed with PBS
were incubated with FITC-labeled insulin (FITC-ins) loaded
BLPs for another 2 h. Finally, the media were removed
from the cells and the co-localizations of BLPs with cyto-
plasmic vesicles were observed by confocal laser scanning
microscopy (CLSM).
In vitro cytotoxicity evaluation of liposomes
The cytotoxicity of the liposomes was examined by
assessing the viability and apoptosis of Caco-2 cells in
the presence of different concentrations of liposomes.
The viability of the cells was measured using the MTT
assay. Caco-2 cells were cultured for 48 h and rinsed
with PBS three times, into which liposomes with vari-
ous lipid levels were introduced. After incubation for
5 h at 37°C, the MTT solution (20 μL, 5 mg/mL) was
added to each well holding cells and continued to incubate
for 4 h. DMSO (200 μL) was added to each well to dissolve
completely the internalized purple formazan crystals
when the medium and excess MTT were removed. UV
absorbance of each well was tested at a wavelength of
490 nm. Cell viability was calculated from the ratio be-
tween the number of cells treated with the liposomes
and that of the control (blank) following the equation:
Cell viability (%) = (Atri/Acon) × 100%, where Atri was theabsorbance intensity of the cells treated with liposomes,
and Acon was the value treated with PBS. The cells treated
with culture medium served as 100% cell viability.
To assess the effect of liposomes on cell apoptosis,
liposomes with different lipid concentrations were added
into the cells and incubated for 4 h. The state of apoptosis
were analyzed by detecting the phosphatidylserine (PS)
translocation of cell membranes using annexin V-FITC
and PI double staining in order to differentiate apoptotic
cells from necrotic cells. The analysis was conducted
by flow cytometry with an annexin V-FITC/PI apoptosis
detection kit (Keygen Biotech, Nanjing, China). Each sam-
ple was repeated three times using 105 cells per test. The
cells treated with PBS were set as the control.
Results and discussion
Preparation and characterization of BLPs
Formulation variables influence the physicochemical prop-
erties of insulin-loaded liposomes such as entrapment
efficiency and particle size [32,33]. It is of high import-
ance to effectively entrap insulin into liposomes so as
to reduce the bulk dosage and avoid waste of drug. The
main variables including lipid/cholesterol ratio, drug/
lipid ratio, the buffer pH upon hydration, and phase ratio
in preparing W/O emulsion were optimized to obtain
liposomes with high insulin entrapment efficiency and
suitable particle size.
Figure 1 shows the effects of preparative variables on
the entrapment efficiency and particle size. The presence
of cholesterol exerts significant influence on the properties
of the lipid bilayers of the liposomes. It is known that
the addition of cholesterol to lipid bilayers decreases
its permeability to water [34]. Suitable lipid/cholesterol
ratio will accommodate more insulin molecules and
generate liposomes with desirable membrane fluidity,
which are helpful to prevent the leakage of insulin from
the internal aqueous compartments. The liposomes with a
lipid/cholesterol ratio of 3/1 or 4/1 produced higher insu-
lin entrapment (Figure 1A). Considering the factors that
influenced drug entrapment and resistant permeability to
water, a lipid/cholesterol ratio of 3/1 seemed to be more
promising. The effect of drug/lipid ratio on the entrap-
ment efficiency is shown in Figure 1B, from which we
could see that the entrapment efficiency increased as the
lipid content increased. Generally, high proportion of lipid
in liposomes can generate more space to host more insu-
lin molecules. Figure 1C showed that the buffer solution
of pH 3.8 used for hydration was most suitable to prepare
liposomes. Lower entrapment efficiencies were obtained
around the isoelectric point of insulin (pH 5.3 to 5.4), which
may be attributed to the loss of insulin because of reduced
solubility. The particle size of liposomes increased as
the pH increased owing to the change of surface charge.
In general, natural phospholipids such as soybean or egg
Figure 1 The effects of formulation variables on entrapment efficiency and particle size. (A) Ratios of lipid/cholesterol and (B) drug/lipid,
(C) pH upon hydration, and (D) organic/aqueous ratio of phase.
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charge density of phospholipids will raise correspondingly,
which results in more electrostatic repulsion that is
unfavorable to form small liposomes. Higher organic-
aqueous phase ratio resulted in higher entrapment effi-
ciency as observed from Figure 1D because increasing
the organic phase was beneficial to the formation of fine
emulsions, which would lead to fine insulin dispersion in
the mixed lipids.
The mean particle size of BLPs prepared under optimal
conditions were about 160 nm and presented a unimodal
distribution (Figure 2A). The morphology of BLPs was
near-spherical as observed by TEM (Figure 2B), though
the liposomes looked somewhat irregular in the TEM
as a consequence of membranous deformation and de-
hydration in sample preparation.Factors influencing hypoglycemic effect of BLPs
The performance of BLPs in decreasing the blood glucose
of rats was affected by a variety of factors. The influences
of particle size of liposomes, biotin-DSPE proportion in
liposomes, and doses orally given on hypoglycemic effect
are shown in Figure 3. As shown in Figure 3A, liposomes
with a diameter about 80 nm almost did not pose a de-
clined blood glucose. The negative result may be the cause
of fragile structure that easily destroyed by harsh GI en-
vironment featured by digestive enzymes and low pH.
However, a significant hypoglycemic effect was observed
when the rats were orally administrated of liposomes of
153.7 nm, the maximal decline of blood glucose level
was up to 38.4%. This enhanced pharmacological action
by BLPs at 150 nm around may be attributed two facets:
(i) improved stability relative to liposomes with a smaller
Figure 2 Particle size (A) and TEM micrograph of BLPs (B).
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thelia, especially by receptor-mediated endocytosis. With
the increase of diameter of liposomes, although the physical
stability was further strengthened, the hypoglycemic effect
of BLPs not only fail to raise but decrease, which may be
caused by larger particle size that was unfavorably absorbed
by epithelia, particularly through vesicle-mediated transport
such as by clathrin-coated pits.
The blood glucose profiles of rats after oral adminis-
tration of liposomes with different biotin-DSPE levels
are shown in Figure 3B. Liposomes with 10% biotin-DSPE,
to some extent, produced the decline of blood glucose
of rats after dosing, whereas more obvious downtrends
occurred in the rats those were given of liposomes with
biotin-DSPE above 20%. However, there was no significant
difference between the liposomes composed of 20% and
30% biotin-DSPE in terms of hypoglycemic effect. The
hypoglycemic effect produced by liposomes with 10%
biotin-DSPE weaker than that of liposomes with more
biotin-DSPE may be as a consequence of relatively weak
stability rather than the insufficiency of ligand amount,
because DSPE that possesses a high phase transition
temperature could reinforce the rigidity of liposomes if
more biotin-DSPE was incorporated into lipid bilayer.
However, since there was not much difference in thestability of liposomes, increasing the amount of biotin-
DSPE is not helpful to the absorption of liposomes, which
could also be deduced from the results of hypoglycemic ef-
fect using liposomes containing 20% and 30% biotin-DSPE
that presented similar profiles of blood glucose decline.
The changes in the blood glucose level of rats after oral
administration of different doses of BLPs are displayed in
Figure 3C. Below the dose of 20 IU/kg, the hypoglycemic
effect of BLPs increased with the increase of oral dose, pre-
senting a dose dependency. At high doses above 20 IU/kg,
however, the in vivo hypoglycemic effects of BLPs were
maintained in the analogous level and seemingly arrived to
a plateau. The phenomenon that the hypoglycemic effect of
BLPs linearly correlated with the dose given at low doses
and expressed nonlinearity at high doses may be ascribed
to the saturability of biotin receptors on enterocytes.
Enhanced hypoglycemic effect of insulin via BLPs
The hypoglycemic effects in normal rats are shown in
Figure 4. Subcutaneous (s.c.) injection of insulin solution
produced rapid blood glucose decrease to about 50%
of normal level in the first 2 to 3 h, and then quickly
rebounded to normal level. Due to significant GI diges-
tion, oral administration of free insulin showed little
hypoglycemic effect. The blood glucose fluctuated, possibly
Figure 3 Profiles of blood glucose in rats after oral administration
of insulin-loaded BLPs. Different particle sizes (A, 20 IU/kg), biotin-DSPE
proportions (B, 20 IU/kg), and doses orally given (C).
Figure 4 Blood glucose levels in rats after administration of
insulin solution and insulin liposomes (the mean ± SD, n =6).
Figure 5 Effects of insulin saline and insulin-loaded liposomes
on TEER of Caco-2 cell monolayers. Group treated with DMEM
as reference.
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maintained at the normal level thereafter. Oral CLPs just
resulted in a slight drop in blood glucose level, though oral
administration of BLPs produced gradual glucose decrease
to about 60% of the normal level at 8 h. However, the blood
glucose of rats discontinued to decrease owing to the com-
pensatory mechanism that could actuate the decompositionof glycogen to compensate for the loss of blood glucose.
The relative pharmacological bioavailability of BLPs,
calculated by the trapezoidal method, was 11.04% with
s.c. insulin as the reference, for CLPs just 2.09%. This
result highlighted the effectiveness of biotin modifica-
tion on the absorption of insulin-loaded liposomes.
Potential absorption mechanism
In previous studies, enhanced cellular uptake and in-
ternalization by specific clathrin-mediated endocytosis
was found in terms of BLPs, and the enhanced perform-
ance had nothing to do with the opening of intercellular
tight junctions [30]. To further interpret the absorption
mechanism of BLPs, we executed another several cell
experiments to deepen the prior results.
In order to clarify whether the paracellular pathway
responsible for the enhanced oral delivery of BLPs, we
investigated the influence of BLPs on tight junctions by
Figure 6 CLSM observation of the co-localization of Rhodamine-labeled BLPs into endosomes. The co-localizations of BLPs with
Rab5/Rab7 are presented in yellow fluorescence.
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shows the TEER changes of Caco-2 cell monolayers after
incubation with insulin saline and insulin-loaded liposomes.
In comparison with insulin saline, two kinds of liposomes
merely caused a transient decline of TEER of Caco-2
cell monolayers upon incubation, whereas the extents in
decline were relatively low, which may result from the
alternation of media that motivated the increased cell
activity. After 45 min, the TEER of Caco-2 cell mono-
layers was restored to the initial level, while a similar
process happened in the group treated with insulin saline.
However, there was no significant difference between
BLPs and CLPs in the alteration of TEER, indicating thatFigure 7 CLSM observation of the co-localization of FITC-ins-loaded B
co-localization of lysosomes with BLPs.the enhanced oral absorption of BLPs was not caused by
the opening of tight junctions.
As the best knowledge known, receptor-mediated endo-
cytosis is a process of internalization of extracellular mole-
cules during which vesicles, for example endosomes and
lysosomes, are formed, which is highly characteristic for
receptor-mediated endocytosis [35]. The co-localizations
of BLPs with endosomes by CLSM observation are shown
in Figure 6. The yellow areas, typifying the co-localization,
were found to locate either in early endosomes or in late
endosomes after incubation with BLPs, clearly stating that
BLPs after being internalized into cells is experiencing
membrane-associated protein-coated pit invagination toLPs into lysosomes. The yellow color in the overlay denotes the
Figure 8 Cell viability of Caco-2. Incubated with BLPs or CLPs at
different lipid concentrations as well as insulin saline for 4 h. (n = 3).
Figure 9 Distribution of cells in different apoptotic stages treated wit
annexin V signals as FL1 and propidium iodide (PI) signals as FL2.
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was mainly distributed over the boundary area in the
early endosomes; however, in the late endosomes, the
co-localization had a tendency of transferring the cyto-
plasm inward, indicating the disassociation of coating
proteins from the invaginated vesicles. Following the
confirmation of endosome transport, we further inves-
tigated the intracellular trafficking of BLPs using Lyso
Tracter® Red, a tracing marker of acidic organelles. The
co-localization of BLPs with lysosomes is presented in
Figure 7. It could be seen that FITC-ins-loaded BLPs
entered into the liposomes and the lysosomes were ex-
plicitly labelled into red. An overlay (yellow) of green
representing FITC-ins-loaded BLPs and red represent-
ing lysosomes was observed, which indicated that the
intracellular trafficking of BLPs after the formation of
late endosomes experienced the transport from late
endosomes to lysosomes. The abovementioned facts
provided solid proof that the oral absorption of BLPs
was facilitated by biotin receptor-mediated endocytosis.h liposomes at different lipid concentrations for 4 h. Collection of
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Regarding the biomaterial of biotin-DSPE, we have not
much information about its toxicity; hence, it is necessary
to evaluate the cytotoxicity for the sake of oral safety.
Figure 8 shows the cell viability of Caco-2 cells after in-
cubation with insulin preparations. No obvious cytotox-
icity was observed for insulin solution or insulin-loaded
liposomes after a 4-h incubation when compared to the
negative control. The cell viability of the insulin solution
group still remained above 95%, and two liposomes had
negligible difference in cell viability relative to insulin
solution under various lipid concentrations. Besides, the
cytotoxicity of BLPs was on close level in comparison
with CLPs, indicating that the biotinylation of liposomes
did not bring extra toxicity. Furthermore, the desirable
biocompatibility could also be judged from the result of
apoptosis of Caco-2 cells (Figure 9). The effects of BLPs
and CLPs at three lipid concentrations on the apoptosis
were relatively insignificant relative to the negative control.
In quadrant 4 (Q4) betokening the early apoptotic cells,
there were no positive signals detected either for BLPs or
CLPs, declaring that liposomes, whether being biotinylated
or not, did not significantly cause the apoptosis of cells.
Although some late apoptotic cells were observed in Q2,
they may come from the necrotic cells as a result of natural
mortality of cells rather than the apoptosis induced by lipo-
somes. The results indicated that biotin-modified liposomes
had a good oral safety for insulin delivery.
Conclusion
This research provided insight into the potential of bio-
tinylated liposomes as novel nanocarriers for oral insulin
delivery. Liposomes prepared under optimal conditions
can effectively entrap insulin into the inner aqueous cavity
and improve the stability of transportation through the GI
tract. By biotinylation, the GI absorptive feature of lipo-
somes was notably enhanced. Significant hypoglycemic ef-
fect was observed in rats in comparison with CLPs after
oral administration of BLPs, especially using liposomes with
a particle size about 150 nm. The enhanced oral delivery of
insulin was mainly ascribed to ligand-mediated endocytosis
by targeting to biotin receptor on enterocytes.
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